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31. Executive summary
The INCF Secretariat organized a workshop to focus on the “role of neuroinformatics in the processes of building, 
evaluating, and using genetic animal models for brain diseases” in Stockholm, December 13–14, 2009. Eight sci-
entists specialized in the fields of neuroinformatics, database, ontologies, and brain disease participated together 
with two representatives of the National Institutes of Health and the European Union, as well as three observers 
of the national INCF nodes of Norway, Poland, and the United Kingdom. Further, the INCF Governing Board chair, 
Prof. S. Grillner, and the former executive director of the INCF, Prof. J. Bjaalie, contributed to defining the format and 
general objectives of the workshop.
Findings
The participants of the workshop reported on the perceived needs and challenges in the field that can be ad-
dressed by neuroinformatics approaches and stimulation or coordination by the INCF. A key finding that emerged 
from the discussions is the increased need for standardized and interoperable database resources, in which differ-
ent modality phenotype data from available disease models and wild type animals can be integrated. The scope of 
the discussions was defined by the different expertise represented by the participants. 
Recommendations
The following recommendations were made:
- Encourage, support and fund work on existing databases and information systems, which need to be linked and 
more easily accessible for researchers to gather information on gene function, expression, variations, and differ-
ences among species to allow easier planning and evaluation of animal models. There are numerous databases 
that cover some aspects of these needs, but gene expression networks in different models, in particular, are not 
easily accessible, and data are difficult to compare among different models. Most importantly, connecting and 
integrating software is needed.
- Encourage, support and fund work on database systems for reporting phenotypes of models.  Such databases 
could be comparable to the DNA gene banks. This requires standardization of phenotype data, which needs to be 
done first, and mandatory reporting of data to the databases (e.g. via agreements with journals for publication). 
INCF should discuss with funding agencies the need for such a database and for coordinated actions.
- Encourage, support, and fund work on connecting “phenotype” databases of models with “molecular” databases. 
During development of the phenotype databases one should ensure that they are directly linked and integrated 
with existing and future molecular databases. In particular, transcriptomic and proteomic databases are still under 
development and need to be integrated. INCF should inform funding agencies of the need for such coordinated 
actions.
- Clearly, the generation of “phenotype” databases requires standards for describing behavior in different strains 
and species. Thus, INCF should encourage, support, and fund work on databases of baseline data from wild-type 
strains for both behavioral and molecular data. INCF should discuss with funding agencies the need for such data-
bases and coordinated actions.
- Encourage, support, and fund the generation of MANGO – a Mouse adult neurogenesis gene ontology database. 
As the role of neurogenesis in initiation and progression of neurodegeneration has not yet been defined, and in 
particular as the rate of neurogenesis in different species and different genetic background needs to be studied in 
detail, the participants supported the idea of MANGO. Close coordination of this activity is needed among Euro-
pean, North American, and Asian funding organizations. INCF should inform funding agencies of the need for such 
a database and coordinated actions.
- Continue to coordinate work with animal models on various aspects of neuroscience (such as neurogenesis, 
linking cell populations and developmental stages across species, etc.) to bring together more experts on one 
subtopic. For example, the INCF could arrange and coordinate further workshops. 
- Arrange annual workshops on large-scale modeling to develop standards for automated home cage behavior. 
Current software development is poor, read-outs are not standardized and technologies are not comparable. Dif-
ferent technologies are on the market, but no comparison has been made. Minimal and optimal standards need 
to be defined to support comparisons among publications. This is also absolutely necessary for comparison of 
preclinical treatment studies. 
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4Because training and teaching are absolutely crucial for all recommendations, INCF should also consider calling 
for funded programs to enhance the entry of bachelors- and masters-degree level scientists and technicians who 
can expedite the construction, population, and curation of the databases envisioned herein.  This could provide 
an impetus for more young people to enter bioinformatics science and would not necessarily require immediate 
expansion of PhD and MD level training programs for these purposes.   
 
Participants at the workshop for Genetic Animal for Brain Diseases, outside the INCF Secretariat, Stockholm, Sweden 
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5Again, neuroinformatics is required to define standard-
ized read outs and to create appropriate databases.
Several scientists contributed their personal views 
about the needs in the field of neurodegeneration and 
the contribution of neuroinformatics. Because this topic 
is rather complex, we will cover only those aspects that 
are represented by the scientific expertise of the partici-
pants of the INCF workshop held in Stockholm Decem-
ber 2009. 
 3. Concepts
To define the “Role of Neuroinformatics in the process of 
generating, evaluating, and using genetic animal mod-
els for brain diseases” more precisely, participants of the 
workshop discussed various readouts and levels of in-
vestigation of models. Here, we define the terms used 
in the context of the models.
Animal model
Modeling plays a major role in neuroscience and in 
particular in neuroinformatics. A broad definition of 
models is provided by the report of the 1st INCF work-
shop on “Large-scale modeling of the nervous system” 
held in December 2006 in Stockholm (www.incf.org). 
At the subsequent INCF meeting in 2009, we focused 
on animal models of brain diseases. For animal models, 
we usually distinguish between biological models that 
provide information about the biological function or 
dysfunction of the studied gene and disease model that 
mimic a human disease. In principle, disease causing 
mutations found in human patients are introduced into 
the germline (so called knock in) of a mouse (or other 
species), the gene is destroyed (knock out model), or 
the endogenous protein is overexpressed (transgenic). 
For each technique, modifications enable the gene or 
the mutation to be expressed at a specified time or in 
a specific cell type. In addition to rodents, non-verte-
brates, such as Drosophila and C. elegans, are used to 
study brain diseases. Recently, zebrafish have provided 
a novel species to study neurodegeneration (see Ring-
berg Symposium at ringberg.web.med.uni-muenchen.
de/schedule/index.html). For cognitive (dys)function, 
monkeys are used in rare cases.
Genetic background
For most human diseases, there is wide variation in the 
age of onset or rate of progression even if two patients 
carry the same disease causing mutation. This is usually 
explained by environmental and genetic background 
factors. In laboratory animals, environment can be con-
trolled fairly well. However, different genetic lines have 
gene variants that lead to amino acid differences or to 
different levels, time course, or spatial pattern of gene 
product expression. 
2. Introduction
Neurodegenerative diseases represent one of the ma-
jor health care challenges of this century. Despite a 
continuously increasing percentage of individuals suf-
fering from these diseases world wide, a therapy is not 
available for most of the conditions. With the rising inci-
dence of neurodegenerative disease, costs for medical 
and sociological care will become significant financially 
for developed countries. Although these change have 
been well known for many years or even decades, rela-
tively small amounts of money have been invested in 
brain research in Europe, compared to the US or Japan. 
Furthermore, the pharmaceutical industry is more in-
terested in drug development than drug delivery into 
the brain and has developed a huge market, such as 
drugs against cancer. Historically, limitations of previ-
ous models of toxic neurodegeneration, such as MPTP 
or 6-OHDA rodent and monkey models of Parkinson’s 
Disease (PD; reviewed in Maries et al. 2003, The role of 
alpha-synuclein in Parkinson’s disease: Insights from an-
imal models. Nat Rev Neurosci 4:727-738; and Capitanio 
and Emborg 2008, Contributions of non-human pri-
mates to neuroscience research. The Lancet 371:1126-
34), and deduced therapeutic neuroprotective strate-
gies have widely failed in the clinic (reviewed in Mandel 
et al. 2003, Neuroprotective strategies in Parkinson’s 
disease. An Update on progress. CVS Drugs 17:729-762).
With the recent identification of genetic causes of sever-
al neurodegenerative diseases, we have a vastly better 
chance to develop novel, genetically modified models 
which may mimic important aspects the human con-
dition much more closely than the earlier toxic mod-
els. These higher translational values of such genetic 
models (as examples see reviews Dawson et al. 2010, 
Genetic animal models of Parkinson’s disease. Neuron 
66:646-661; Ashe and Zahs 2010, Probing the biology 
of Alzheimer’s disease in mice. Neuron 66:631-645) will 
make them more appropriate tools for preclinical test-
ing. However, they first need to be characterized be-
haviorally and neuropathologically in great detail. For 
neuropathological characterization we recommend 
the report from the 1st INCF workshop on Mouse and 
rat brain digital atlasing systems (www.incf.org), even 
though numerous aspects of neuropathology, such as 
sensitivity of different strains and species or even cell 
types to toxic agents such as mutant or overexpressed 
protein, need to be defined. 
In addition to questions about which strain (genetic 
background) is best (pharmacological studies typically 
use out-bred strains, whereas genetic and behavioral 
studies use inbred strains), there is a serious dearth of 
behavioral databases and standardized behavioral pro-
tocols (SOPs), and there is no general agreement on 
readouts for human neurological symptoms in rodents. 
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6In humans, two individuals (except of monocygotic 
twins) can have approximately 3 million different poly-
morphisms. To minimize the influence of genetic varia-
tion in disease manifestation or progression models, 
inbred lines are frequently used. Inbred lines are gener-
ated by extensive inbreeding to reduce genetic varia-
tion. In contrast, outbred lines are used to maintain 
large genetic variability within a population. 
Biomarker
Relative to animal models of human diseases, biomark-
ers are biological compounds that which can be easily 
obtained and measured and that are specific for a dis-
ease or a particular stage of a disease (as an example of 
biomarkers in neurodegeneration see for instance re-
view by Maetzler et al. 2009, Progression of Parkinson’s 
disease in the clinical phase: potential markers. Lancet 
Neurol 8:1158-71). Metabolites, proteins, or RNA can 
provide biomarkers, as well as imaging technologies, 
such as PET.
Automated home cage analyses
Most of behavioral analyses depend on the experience 
of the investigator. Due to handling differences, read out 
of behavior may vary dramatically among investigators 
or even more significantly among different facilities (as 
an example read: Crabbe et al. 1999, Genetics of mouse 
behavior: Interactions with laboratory environment. 
Science 284: 1670-2). These insights led to the develop-
ment of the so-called automated home cage environ-
ment, which allows behavioral analysis without signifi-
cant handling by the personnel. Different systems are 
on the market, one uses a transponder implanted under 
the skin of the animal that allows analysis of several ani-
mals in one cage and thus also study models in their so-
cial environment.  The more widely used cages track one 
animal per cage using infrared beams incorporated into 
the frame of the cage (for review see: Spruijt and De-
Visser 2006, Advanced behavioral screening: automated 
home cage ethology. Drug Discovery Today: Technologies 
3: 231-7). 
Neurogenesis
The knowledge that new neurons are generated in adult 
mammalian brain is recent (Reynolds and Weiss 1992, 
Generation of neurons and astrocytes from isolated 
cells of the adult mammalian nervous system. Science 
255:1707-10). These cells are predominantly generated 
in the subventricular zone of the lateral ventricles and 
in the subgranular zone of the hippocampus. They may 
have a major importance in memory and learning (Kem-
permann et al 2004, Functional significance of adult 
neurogenesis. Curr Opin Neurobiol 14:186-91). Impaired 
neurogenesis may play a role in several neurodegenera-
tive diseases (references).
4. Workshop Discussions
During the workshop we concentrated on how neuro-
informatics can help overcome current limitations of 
models of neurological diseases. We divided the discus-
sion into several parts:
4A. What model systems and species should be used in 
studies of neurodegeneration?
4B. What aspects need to be considered to optimize 
models for studies of human diseases?
4C. How can ontologies and databases help provide 
rapid and integrated access to data about brain dis-
eases?
4A. Models and Species: 
The following issues were discussed:
Choice of species (monkey, mouse, rat, zebrafish, C. el-
egans, Drosophila; for instance, should monkeys always 
be considered as models for brain diseases and should 
they be the last species to be modified). The workshop 
participants had a lively debate about which species to 
focus on in creating comprehensive database(s). The 
discussion concentrated on differences as well as simi-
larities among different species. Some aspects of mice 
make them less advantageous, including the remark-
able variability among currently used mouse strains, 
their highly inbred nature, and their limitations in re-
gards to a) size (e.g.with respect to CSF and blood sam-
pling for biomarker studies) and b) difficulty sophisti-
cated behavioral testing and in vivo electrophysiology. 
The advent of genetically manipulated rats means that 
this species could become increasingly more useful for 
standardized data collection of normal aging and as a 
comparator for studies of mouse models of disease.  A 
similar comprehensive effort could be performed with 
one or two invertebrate animals (worms or flies), and 
some such studies are already well-underway. Neuro-
anatomical differences of mice, monkeys, and humans 
were discussed.  There is reason to suggest that one 
should model particular human diseases only in spe-
cies that have similar neuroanatomical features. As an 
example, species lacking the subtypes of interneurons 
that are affected in schizophrenia in humans are likely 
to be inappropriate models of this disease. On the other 
hand, similarities between species exist for other models 
mimicking human diseases, in particular with respect to 
protein structure. Thus, many aspects of a human dis-
ease can also be studied in species distantly related to 
humans such as C. elegans, zebrafish, and Drosophila. In 
some cases, it is difficult to predict which species should 
be used as a primary choice. On the other hand, for ex-
ample, marmosets are recommended in Alzheimer’s 
Disease (AD) research because most of them develop 
plaques unlike most dogs or vervet monkeys. Of course, 
it is important to define the read out that the model 
should provide. 
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7 • Choice of strain (inbred, outbred) and unsolved is-
sues such as pharmacogenomics, neurogenesis et 
cetera. Is there a need to use different species/strains 
for different diseases or different stages of disease? 
As an important example, differences in neuroneo-
genesis in various mouse strains were discussed. We 
acknowledge that there is only limited information 
about strain differences at this point and strain dif-
ferences are not a major focus of current research. 
Gerd Kemperman crossed BXD80 strains to discover 
neurogenesis loci, distinguishing cis genes (with 
feedback regulation) vs. trans genes (without feed-
back). In general, the importance of neurogenesis in 
neurological diseases is not well studied and needs 
to be investigated widely among different species 
and in the different genetic backgrounds. For the 
INCF, the generation of a mouse adult neurogenesis 
gene ontology database was recommended.
 • Standardization of phenotyping (e.g. automated 
home cage systems, selection of paradigms). Since 
the readouts of “conventional” behavioral pheno-
typing differ substantially between laboratories, 
even when the same strains, equipment, and condi-
tions are used (Crabbe et al. 1999), there is a need for 
standardized behavioral phenotyping. Automated 
(high-content) home cage behavioral analyses have 
emerged as promising new tools to overcome some 
of these limitations, since human intervention is 
minimized compared to stand alone testing (com-
parative analysis). However, behavioral analyses 
need extensive and rigorous descriptions of operat-
ing procedures, and thus metadata recording. The, 
INCF could make a great contribution to the estab-
lishment of formats and standards for metadata de-
positions in this field.
 • Comprehensive collection of factors modifying the 
phenotype requires in depth analysis of multiple 
parameters. This can be achieved by gathering 
multiple data parameters through High Content 
Screening approaches (HCS) that are information 
dense, and medium to high throughput. The fact 
that HCS can be operationalized with well-described 
standard operating procedures makes it suitable 
for cross-lab, cross-experiment, and cross- animal 
model comparison. For animal models, HCS can be 
used in transcriptomics, proteomics, and behavioral 
analysis. However, standards need to be defined.
 • Rating scales for phenotypes (comparable to hu-
man disease readouts). For disease models, and ro-
dents in particular, existing limitations of behavioral 
screens become even more pronounced because 
there are no guidelines for standard ways to mea-
sure movement disorders (e.g. dystonic, ataxic, cho-
reatic, parkinsonian, et cetera.). Automated home 
cage analyses may also provide new insights (for 
example, small differences in rodent behavior may 
be better recognized during the night). 
 • Biomarkers. The potential of biomarkers for defining 
disease, disease onset, or disease progression has 
not yet been fully explored in human patients. This 
is in part due to the high variability of the readouts 
and limited access to tissues, in particular brain tis-
sue. Here, animal models are preferred over humans 
because tissue availability is not an issue, ethical is-
sues are reduced, and developmental brain diseases 
and standardization (sex, age, brain region, genetic 
background aso.) are relatively easily achieved. Im-
aging analyses, such as PET, tracers, and antibod-
ies can be validated as potential biomarkers before 
applying to humans. The participants discussed 
whether monkeys are preferred over rodents sys-
tems for biomarker studies because they are evolu-
tionary more closely to humans. Monkeys, however, 
provided only a limited number of disease models. 
Standard operating protocols are necessary, as well 
as databases to store and compare studies.
 • Neurometabolism and neurotransmitters. Neu-
rotransmitters (can also be considered biomarkers) 
can be studied only in models. Although electro-
physiology was not a topic of the workshop, it is 
closely linked to neurometabolism and neurotrans-
mitters and can be used in vivo in models. In vitro, 
specific neuronal or glial cell populations can be 
isolated from disease models, grown, and recorded 
with patch electrodes under various conditions, thus 
contributing significant information about diseases.
 • Generation of databases for phenotypes and bio-
markers of disease models. Currently, no database 
and no standards exist for reporting phenotypes 
and models, not even for a particular disease with 
the exception of some lay organizations that have 
collected data from the literature on existing mouse 
models (CHDI for Huntington’s disease or Michael J 
Fox Foundation for Parkinson’s disease).  These data 
are, however, not collected in a standardized way 
and the raw data are not reported. The participants 
strongly recommend also reporting negative data 
on models, which should also be entered into data-
bases to preclude repeated attempts to characterize 
specific models. 
 • Databases connecting molecular with behavioral 
phenotypes are lacking. Together with the lack of 
databases on phenotyping, there is a strong desire 
for databases which have the potential to link all 
large data sets from these models, including tran-
scriptomics, proteomics, neurometabolites, imaging 
data, etc. Such higher level systems will expectedly 
be instrumental for the integration of different data 
modalities into new knowledge.
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84B. Optimizing Models:
Given the problem of choosing which genetic back-
ground and readout to use in wild-type animals, the lack 
of databases to store extensive phenotype data, and the 
absence of a connectivity database with molecular data 
sets, the problems with genetic models are obvious and 
difficult to solve: How to define different diseases based 
on symptoms as specific readouts? All diseases in hu-
mans have a range of early onset signs which may dif-
fer among patients. Also, not every patient manifests all 
signs. Furthermore, some diseases manifest differently 
at different ages (for instance Huntingtons’s disease in 
early age manifests spastic rather than barely chore-
atic movement disturbances). For animal models this is 
even more complex. We do not have choreatic, ataxic, or 
dystonic symptoms, but rather movement disturbances 
in general. Subtle signs which can be provoked in hu-
mans by asking to perform specific tasks may thus be 
difficult or not at all visualized in models. Sophisticated 
behavioral tests can be done only in species like rodents 
or monkeys. 
In addition to these biological limitations, we also have 
model-dependent problems to be solved. Some of 
these issues are (i) for transgenic animals, publication 
of the level of expression of the transgene, (ii) clear 
description of the promoter used, (iii) DNA integration 
sites, (iv) inventory of the phenotypes over time and 
not only until first symptoms appear, (v) description of 
unchanged or normal or phenotypes, (vi) description of 
the genetic background, and (vii) cross-breeding into 
different background strains. There is currently no rec-
ommendation for which strains to use for different dis-
eases. Although most genetic association studies need 
to be confirmed in a different population, phenotype 
studies in mice are typically conducted only once and in 
only one laboratory. For studies of cognition, are mice 
really the appropriate species? Recently, the tendency 
is to generate complex genetic models to mimic human 
neuropathology and analyze of genetic pathways bet-
ter, but as a result, the readouts become more complex.
Anything learned about disease models can be overlaid 
with what is culled from the healthy animal databases. 
Thus, for INCF, creation and phenotyping of animal 
models of specific diseases necessitates creating useful 
databases of “normal” (healthy) animals over their lifes-
pan.
What is needed is an internationally accepted standards 
for how to generate models (transgenic cDNA, trans-
genic BAC, knock in, knock out, level of expression) and 
analyze models. 
What is needed for good models of neurodegenerative 
diseases?
 • Centralized neuropathology facilities; standards op-
timized for translation to and comparison with hu-
man neuropathology 
 • Typical human phenotype to be “translated” into an 
animal model
 • Cell death / opposed to neuronal dysfunction
 • Useful readouts (biomarkers) for evaluation of exper-
imental treatment and preclinical studies
Discussion extracts
 • It was pointed out that that the standards main-
tained in human clinical trials needs to be introduced 
to the field of animal model research (database of 
protocols). The emphasis should be on pathway 
analysis, from neuroinformatics, functional genomics 
(gene-chip, mass spectrometry, antibody array), and 
behavioral studies of cognitive decline, to establish-
ment of database systems holding a range of pheno-
type data (in vivo histobiochemistry, monitoring of 
disease proteins over time using microdialysis). 
 • Models also have a lot of variation precluding robust 
translation from models to humans. Reference popu-
lations to deal with this issue (for both humans and 
models) are necessary.
Preliminary conclusion: 
We need a discussion about whether it is favorable to 
use several species and one readout or one species and 
several readouts. Most likely, pre-clinical studies should 
include many read-outs and several models, preferen-
tially even in different species. 
There is great need for comparing different existing 
models of a disease in one laboratory or even more than 
one laboratory. This is not ground breaking research, 
but it needs to be done.  It is difficult to get funding 
agencies to finance this work. This work requires coordi-
nation of different disease groups in an integrated man-
ner. Also before models are used for pre-clinical studies, 
they need to be confirmed by an independent, certified 
behavior laboratory. Finally, a consensus conference of 
experts is needed to choose a few models to be used 
and to get funding agencies in agreement. Additionally 
challenges would be to achieve agreement among re-
searchers and to supply the models. Because data need 
to be publicly available, strong input from the INCF in 
database creation would be preferable. 
4C. Databases and Ontology:
Several important questions were discussed: How well 
are current databases prepared to reflect the complex-
ity of the brain in terms of gene regulation and protein 
networks, including epigenomics? How can they be 
linked to behavior? How can behavior of models be 
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9linked to human symptoms? Understanding progres-
sion of a disease in humans requires many patients, 
which need to be investigated with sophisticated meth-
ods over a long time. Do diseases progress in a similar 
way in animal models? Based on normal functional net-
works, how deep is our understanding, and how can the 
INCF contribute to brain diseases, particularly neurode-
generative brain diseases?
The workshop participants appeared to share the con-
cern that it is very difficult to compare and integrate 
data from existing databases, because of different for-
mats and rules for populating the databases and incon-
sistent use of ontologies.  Although it seems impossible 
to change what already exists, new databases should 
draws upon accumulated experiences, and strive to ad-
here to systematic standards for their construction.
Discussion extracts
 • We are missing ways of defining and comparing 
molecular phenotypes (between species) as well as 
systematic digital atlas resources for disease models. 
We need resources for identifying morphological dif-
ferences between species. Because most neurode-
generative diseases in humans are age related, one 
should run longitudinal studies until late ages of the 
models. Although preferentially done in monkeys, 
this model is still not widely used and may have been 
avoided due to ethical concerns. However, digital 
atlases of morphology, histopathology, and gene ex-
pression should be built for rhesus monkey as well.
 • Ontologies lack standards to describe phenotypes 
in models. Comparisons between species are funda-
mentally impossible. Links among altered cell types, 
neurophysiology, and phenotypes does not yet exist. 
The participants questioned whether the data of the 
Jackson Laboratory would be useful for a first step in 
this direction.
 • It was suggested to introduce a standardized vo-
cabulary as well as methodologies for animal models 
and the construction of translation tables between 
models and human disease.
 • The question was raised whether it would be pos-
sible to visualize activities of particular neurons as-
sociated with conditioning experiments, for instance 
expression of genes in the habenula (in fish) might 
be related to psychiatric diseases. It was suggested 
that experiments could go back and forth between 
fish and human as a means to contribute to under-
standing psychiatric diseases.
 • One should introduce dimensions for evaluation of 
species: axes, relevance, efficiency, phenotypes, and 
age. The reuse of model data has not really been fore-
seen. It was emphasized that differences among hu-
mans (many genetic subpopulations) and the many 
treatments used necessitate a robust translational 
bridge from model to human (work with types rather 
than subpopulations). Models have a lot of variation 
as well, making robust translation from models to 
humans difficult.  Thus, as mentioned under point 
1, above, use of reference populations to deal with 
this issue (for both humans, and models) is strongly 
encouraged. However, translation will be needed be-
tween populations.
 • Anatomical atlases should be linked with gene ex-
pression, proteomic, etc. atlases and also with behav-
ior and imaging. To this end well-defined, interoper-
able spatial reference systems (such as the mouse 
brain Waxholm space, and Thalairach coordinates in 
primates) are needed.
 • ”Google earth for the mouse brain” as a neuroscience 
information framework is needed.
 • An important step would be to register all databases 
at one Internet site to support easier access to exist-
ing data (www.komp.org).
5. Concluding Remarks
Compared to recent studies in humans (large-scale 
genetic studies including whole genome sequencing, 
epigenomics, epidemiology, and sophisticated pheno-
typing with biomarkers related to the transcriptome 
and to imaging), characterization of animal models lags 
significantly behind. Although it is generally accepted 
not to use control individuals from a different popula-
tion in human GWA (genome-wide association) studies, 
we still do not know precisely which strain of mice or 
rat is the best model for neurodegenerative diseases. 
Phenotyping of wild-type strains is lacking, as well as 
databases and developmental information. Technology 
is still developing. For imaging, tracer load is mostly ex-
perimental. The genomes of various species and strains 
within a species, and their genetic backgrounds are 
largely not yet available. Here one would need a com-
bined effort to have all information on phenotyping and 
genome from all potential species and different genetic 
backgrounds (mice, rat, C. elegans, Drosophila, fish, and 
some monkeys) and a consortium which decides the 
primary focus. The most recent report on sex-specific 
parent-of-origin allelic expression in the mouse brain 
(Gregg et al. 2010, Sex-specific parent-of-origin allelic 
expression in the mouse brain. Science 329:682-5; Gregg 
et al. 2010, High-resolution analysis of parent-of-origin 
allelic expression in the mouse brain. Science 329:643-8) 
highlights the necessity to truly integrate genetic and 
behavioural data into a single database.
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6. Workshop Program
Roles of Neuroinformatics in the process of building, evaluating and using genetic animal models for 
brain diseases.
Chair: Olaf Riess
PROGRAM
Sunday, December 13, 2009
12:00 – 13:00  Lunch and Welcome
13:00 – 13:30  Introduction of INCF and the Goal of the Workshop
  (Sten Grillner, Chair of INCF Governing Board)
  (Olaf Riess, University of Tuebingen)
13:30 – 14:00  What makes a good genetic model for human brain disorders
  (Olaf Riess, University of Tuebingen)
14:00 – 14:30  Use of genetically modified mouse model to study the biochemical
   mechanisms of neurodegeneration in Alzheimer’s and Parkinson’s
  (Dennis Selkoe, Harvard Medical School)
14:30 – 15:00  Use of non-human primate model to identify specific networks of
  gene expressions in areas of the developing cerebral cortex involved in the higher brain functions
  (Pasko Rakic, Yale School of Medicine)
15:00 – 15:30  Coffee
15:30 – 16:00  Zebrafish and mouse models of human Usher syndrome and zebrafish database to develop 
  informatics support for zebrafish models of human diseases
  (Monte Westerfield, University of Oregon)
16:00 – 16:30  Zebrafish as a model animal to study neural circuits against fear
  (Hitoshi Okamoto, RIKEN Brain Science Institute)
16:30 – 17:00  A new paradigm for animal models in personalized medicine
  (Rob Williams, University of Tennessee)
17:00 – 17:30  Systems biology of activity-dependent brain plasticity
  (Gerd Kempermann, University of Dresden)
Monday, December 14, 2009
9:00 – 9:30  High content systems analysis of brain diseases
  (Guus Smit, Vrije University Amsterdam)
9:30 – 10:00  Anatomical phenotyping of transgenic models
  (Trygve Leergaard, University of Oslo)
10:00 – 10:30  Informatics and genetics programs supported by NIH
  (Jonathan Pollock, Division of Genetics, National Institute on Drug Abuse, National Institute 
  of Health, USA)
10:30 – 11:00  The EC contribution towards elucidation of human disease using mouse models
  (Christian Desaintes, Directorate General for Research, European Commission and Co-chairman,   
  the steering committee of the International Knockout Mouse Consortium)
11:00 – 11:30  Coffee
11:30 – 12:30  Discussion: state-of-the-art for genetic animal models for brain diseases and current role of 
  neuroinformatics in the process
12:30 – 13:30  Lunch
13:30 – 17:00  Discussion:
  (a). future developments for genetic animal models and roles of neuroinformatics
  (b). potential contributions of INCF
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7. Appendix 
Sustainability Issues – summaries of 
speaker presentations
Numerous recommendations of the participants have 
been integrated into sections 1-5 of the report. Here, we 
provide more discussion of individual perspectives and 
views.
Hitoshi Okamoto
1: Establishment of a brain atlas for precise correlation of 
individual parts of the brain among different model ani-
mals
The triune brain theory has advocated that the brain 
has expanded its capacity by adding new parts dur-
ing evolution. This process has culminated in the gen-
eration of the neocortex in the mammalian brain. How-
ever, the recent discovery of remarkable conservation 
among all vertebrates, i.e. teleost fish, birds, and mam-
mals, of the expression patterns of the so-called tool kit 
genes, the essential genes that mastermind patterning 
of the brain during embryonic development, has chal-
lenged this prevailing view. Conserved expressions of 
these genes in the pallium and subpallium among dif-
ferent species has strongly suggested that the basic 
structures of the telencephalon derived from the pal-
lium and subpallium, such as those corresponding to 
the basal ganglia, hippocampus, amygdala, and isocor-
tex are shared more universally by all vertebrates than 
previously thought. This idea has forced us to think that 
many complex behaviors of animals may be regulated 
by neural circuits analogous to the circuit that controls 
the so-called higher brain functions of the human brain.
•	 This new view has suggested that we may be able 
to study the neural mechanisms of at least some of 
complex behaviours controlled by higher brain func-
tions and the mental illness caused by malfunction 
of such by using non-mammalian vertebrates, which 
have smaller and simpler brains that are more easily 
amenable to genetics than mammalian brains. 
•	 Zebrafish (Danio rerio) is now getting much atten-
tion as a newly emerging model animal for studies of 
neural circuit functions both in normal and impaired 
states, such as goal directed behaviour, decision mak-
ing, choice of proper fear responses against aversive 
stimuli, and psychiatric diseases such as depression, 
PTSD, and drug addiction. 
•	 The community of the people using zebrafish has 
already made great efforts to compile information 
systematically about the whole genome sequence, 
expression patterns of almost all genes and markers 
genes in transgenic lines, and phenotypes of the mu-
tants. A new initiative to establish an international 
resource of lines with mutations in all genes is under-
way. The results of such efforts should be linked with 
the international neuroinformatics initiative.
•	 It is now imminently necessary to provide informa-
tion that can facilitate comparisons among different 
model animals. Currently, it is not clear how each 
part of the zebrafish brain precisely corresponds 
to the parts of the mammalian brain. For example, 
it has only recently become clear from the study of 
gene expression patterns and afferent and efferent 
neural connections that the ventral habenula of the 
zebrafish diencephalon corresponds to the lateral 
habenula of mammals. Knowledge accumulated by 
such efforts should be annotated in the brain atlas of 
zebrafish to enable phylogenetic comparisons.
This recommendation should also be extended to other 
emerging model animals such as song birds. 
2: Neural connectomics 
Technology such as neural circuit genetics or optoge-
netics, with which we can conditionally inactivate or 
activate of any parts of neural circuits using genetic 
manipulation and viral transfection has opened an en-
tirely new field of neuroscience that enables deeper un-
derstanding of brain function on the basis of causality 
rather than parallelism. These technologies are already 
feasible in various animals such as mice, rat, primates, 
and zebrafish. To make this technology more available, 
it is important to annotate each part (nucleus) of the 
brain map with information such as available Cre-lines 
in the case of mouse or enhancer trap lines in the case 
of zebrafish.
Efforts to establish whole-brain neural connectomics 
both at light and electron microscopic levels will soon 
require a new technology to handle the huge amount 
of information. Such technology is essential not just for 
professional researchers who integrate the information 
for reconstruction of 3-D images, but also for general 
users with only a limited capacity to access the large 
amounts of neural connectomics data through the con-
ventional Internet.
3: Establishment of centralized site for researchers to find 
information around the world 
Currently, many information sites are run by indepen-
dent agents. Although we can find such sites with vari-
ous searching software, it is difficult for non-experts to 
find which sites are useful for which particular purposes. 
For examples, modern neuroscience needs access to 
new technologies that are being developed continu-
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ously. It would be convenient to provide centralized site 
where researchers can obtain advice as to which sites to 
visit to find information on particular subjects, such as 
optogenetics, virus vectors, etc. This may be possible by 
designating individuals to collect and update informa-
tion regularly.
Dennis Selkoe 
Long-term recommendations (difficult to achieve and re-
quire new funds):
1. INCF should strongly encourage standardization of 
methods and terms during construction of new data-
bases for animal models internationally.  Consider issu-
ing a set of recommended guidelines and standards for 
animal database construction through a “white paper” 
written by 10-20 leading neuroinformaticians convened 
by INCF, with publication in a peer-reviewed journal.
2. INCF should work with other neuroinformatics efforts 
to lead the creation of a comprehensive database fo-
cused on one or two commonly used strains of healthy 
rats. Try to achieve a consensus as to which strain(s) to 
choose. The healthy rat database should include data 
on the genome (and possibly the epigenome), tran-
scriptome, proteome, and neuronal connectome of the 
normal rat brain [organized by brain regions and later 
by discrete neuronal populations (nuclei)]. It could be 
complemented by a database of results of standardized 
behavioral tests performed on healthy rats at four ages: 
3, 9, 18 and 30 months (if possible).
Short-term recommendations:
INCF should consider convening a consensus group 
of leading informatics-oriented investigators who use 
mouse models of human neurodegenerative diseases, 
especially for Alzheimer’s disease and Parkinson’s dis-
ease. The goal would be to evaluate critically which ex-
isting mouse models are the most compelling and use-
ful and which should be deemphasized. A white paper 
could be issued, recognizing that some in the field may 
choose to disregard it (to their peril!). This workshop 
could also discuss the utility of rats for neurodegenera-
tive disease modelling at this point in time.
Gerd Kempermann
Standard operating procedures (SOPs) are useful, when 
they serve the community to reach consensus about 
results from a particular experiment. Only with clear 
standards can the results from different groups become 
comparable and the work cumulative. On the other 
hand, too much focus on SOPs can prevent original-
ity and steer a field into wrong directions. SOPs should 
also not become yet another type of artificial hurdle for 
publications. What journals and grant agencies should 
enforce are standardized descriptions of materials and 
methods (preferably based on ontology). The tendency 
of many major journals to neglect the importance of 
clear descriptions of experimental procedures needs to 
be counteracted. 
At a very fundamental level the elementary data sets, 
be it gene arrays or proteomics data require careful 
and obsessively curated annotations. Otherwise many 
attempts for systems biology will ultimately fail. Exon 
arrays and deep sequencing, for example, generate in-
formation about great numbers of previously unknown 
splice variants. Posttranslational modifications further 
dilute the identity of a particular gene. So far, array com-
panies have paid little to no attention to annotations, 
leading the existence of large numbers of incorrectly 
assigned probesets and thus false conclusions. Such 
errors multiply, when based on such data the attempt 
is made to integrate across experimental domains and 
platforms.
With the rise of systems biology and the availability of 
enormous data sets spanning diverse domains of sci-
ence, one single analysis might draw from results ob-
tained from experiments based on very different, po-
tentially conflicting assumptions. At the same time, with 
the change in scale, from molecular and below to organ-
ismic and cultural, new rules and “laws” govern and any 
attempt of synthesis is destined to generate conflicts or 
paradoxes. While it has been widely acknowledged that 
databases need to learn to “talk to each other” in order 
to integrate the many different available types of infor-
mation, less attention has yet been given to the theo-
retical concepts of how such integration across scales 
is at all possible. Rules for this type of analysis need to 
be developed, otherwise the attempted integration will 
lead to spurious connections and the resulting relation-
ships cannot be interpreted.
Monte Westerfield
One of the major impediments to developing animal 
models of human disease is the availability of informa-
tion about human disease phenotypes. It is relatively 
straightforward to develop an animal model when the 
disease causative genes are known. However, develop-
ing animal models of human diseases with unknown 
genetic causes is frustratingly difficult.  There have been 
a few recent attempts to make human disease pheno-
types “computable”, including the Human Phenotype 
Ontology (HPO), the human disease ontology (DO), and 
the Phenotype And Trait Ontology (PATO), but to date, 
there is no systematic approach and, hence, very few 
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diseases have been annotated. The development of 
multiple seemingly parallel ontologies and methods 
suggests that standards are needed.  
Similarly, there are no uniform guidelines for the types 
of assays used for phenotypic characterization of animal 
models of human diseases. Here, too, a lack of standards 
means that information obtained in one study may not 
be easily compared with data from other studies, nor 
can it be searched or analyzed computationally. 
Recommendations:  
1. The INCF should coordinate the establishment of on-
tologies and standards for describing human brain dis-
ease phenotypes.  
2. The INCF should coordinate the establishment of rec-
ommended standards for phenotypic analyses of ani-
mal models of human brain diseases and for the meta-
data that describe how the assays were conducted, the 
units of measurement, data formats, etc.
Trygve B. Leergaard
Anatomical phenotyping of transgenic models
Transgenic rodents models of neurodegenerative dis-
ease are considered to be powerful tools for experi-
mental investigation of fundamental neuropathological 
processes and for evaluation of potential therapeutic in-
terventions. The value of such models is largely related 
to the degree with which a human disease phenotype is 
reproduced in the animals. As with human patients suf-
fering from neurodegenerative disease, animal model 
phenotypes are typically characterized or ‘diagnosed’ 
by behavioral analyses, neuroimaging, and post mor-
tem histopathological examination. 
Although invasive experimental manipulations and 
detailed histological examinations can be routinely 
performed in the rodent brain, its relatively small size 
is a limiting factor for neuroimaging approaches. There 
are different motivations for determining the anatomi-
cal phenotype of a transgenic rodent model, and the 
choice of methods varies according to purpose. General 
validation of transgenic models is often based on his-
tological detection of disease specific markers, such as 
e.g. regional neurodegeneration or protein accumula-
tions. Exploration of underlying pathological processes 
at level of molecules, cells, or brain systems, will usually 
require more sophisticated experimental approaches. 
In context of evaluating disease progress and the effect 
of (therapeutic) experimental interventions, sensitive 
in vivo biomarkers are needed as benchmark readouts. 
To this end, positron emission tomography and differ-
ent magnetic resonance imaging (MRI) techniques have 
been employed with variable success, with diffusion 
based MRI possibly appearing as the most promising . 
Thus, anatomical phenotyping approaches cover a wide 
range of methods and levels, which can be utilized in 
context of exploratory mapping studies or more fo-
cused hypothesis driven investigations. There are many 
parallels to human clinical investigations, but the lack 
of consensus about which criteria a transgenic animal 
should fulfill to qualify as a specific disease model, and 
the inevitable variations in phenotype, make neuro-
anatomical investigations in transgenic animals more 
challenging. In contrast to traditional qualitative and 
descriptive anatomical characterizations in normal ani-
mals, phenotyping efforts in transgenic animals require 
quantitative readouts and higher numbers of experi-
ments to allow statistical group comparisons. The com-
bination of increased efforts and results with restricted 
validity, give added costs and risks as compared to simi-
lar investigations in normal animal. 
Novel methods including high-resolution MRI, auto-
mated image analyses, histological image databases, 
and digital brain atlases will likely allow more efficient 
anatomical screening. It should therefore be possible 
to industrialize anatomical phenotyping to a certain 
degree, for example by establishing high-throughput 
pipelines producing numerical data about e.g. brain 
region volumes, specific cell numbers, or chemoarchi-
tectonic features. However, given the multiple levels 
complexity in this field, specifically tailored hypothesis 
driven (multi-modal) investigations will remain funda-
mental, and should probably be conducted within con-
sortia of collaborating experts. 
Guus Smit
High Content Analysis
Identifying novel molecular targets in animal models 
of disease needs standardization and in depth analysis 
of multiple parameters. This can be achieved through 
High Content Screening approaches. HCS is not the 
same as High Throughput screening; HCS gathers data 
on many parameters, is information dense, and is me-
dium to high throughput. The fact that HCS can be op-
erationalized with well-described standard operating 
procedures makes it suitable for cross-lab, cross-exper-
iment and cross- of animal model comparison. HCS can 
be used in systems biology approaches for a multilevel 
analysis, e.g., using Cellular assays, Proteomics analysis 
and Behavioral assays.
Cellular assays
HC cellular technologies, such as the ArrayScan (Cello-
mics), are valuable functional screening intermediates 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
90
9.
1 
: P
os
te
d 
19
 A
pr
 2
01
1
14
for neuronal genes e.g., in involved in neuronal growth 
and survival. HC cellular technologies can be used for 
many types of intracellular assays (e.g. protein translo-
cation, receptor activation, etc). Through these technol-
ogies new molecular disease targets will come available 
which can be followed up for drug screening.
Informatics Needs: The data that come available at vari-
ous sites needs standardized minimal data set descrip-
tions. At present these are not yet routinely provided. 
In particular combinatorial tests for genetic modifiers 
would benefit from metadata storage, data sharing and 
across platform operability. Also a central portal, gath-
ering data from cellular screening stored in local data-
bases, is not available.
Synaptic proteomics
The synapse is a unique neuronal organelle which func-
tion can be accessed through various different tech-
nologies. This is of relevance since synaptopathologies, 
diseases of the synapse, are found in all areas of neuro-
logical and neuropsychiatric diseases. The synapse has 
experimental and computational challenges. For these 
it is necessary to establish quantities, stoichiometries, 
interactions of synaptic proteins through new mass 
spectrometric and proteomics technologies.
Informatics Needs: Synaptic proteins need to be an-
notated and databased (G2C, SBS-DB, etc). Through 
European funding of synapse-focused consortia (e.g. 
Eurospin, and SynSys) it is expected that the basis for 
adequate synaptic protein ontology will be laid. A Euro-
pean database for the synapse will be generated where 
future development will be towards integrating differ-
ent types of information (e.g. molecular, physiology, 
perturbations).
Synapses have a unique composition, depending on 
various dimensions, e.g., genotype (animal model), 
brain area, age, stimulus, etc. As such, data on synaptic 
proteins should relate to spatial info (e.g. by linking it to 
a brain atlas), should have proper metadata description 
for genotype, disease mutation, brain area studied, pro-
tocols for studying molecules and physiology. 
A specific area of interest will be to map the dynamic 
properties of synapses, e.g., changes in phospho-pro-
teome signatures or stimulus-dependent dynamics of 
protein complexes. This requires description of types 
of stimuli (protocols), which again needs metadata de-
scription. Most of the aforementioned requirements are 
still in the early days of development.
A systems approach of the synapse requires coupling 
to synaptic physiological data obtained. This type of in-
tegrated analysis of data does not exist yet, and needs 
specific tools to be developed.
Behavioral analysis
Behavioral analyses need rigorous description of oper-
ating procedures, and thus metadata deposition. Auto-
mated home cage behavioral analysis (high content) is 
coming up as a new promising tool, as it is minimally 
depending on human intervention compared to stand 
alone testing (comparative analysis). 
Informatics Needs: A specific requirement for high con-
tent behavioral analysis is the use of multivariate statis-
tics on long-term multiday behavioral data sets.
There is local storage of data and for instance for genetic 
resources there is GeneNetwork available for correlative 
analysis and data sharing. Standardization of methods 
is still not complete, even given various EU projects in 
this area. Specific need is the central deposition of be-
havioral (meta-)data.
Informatics challenges 2010-2020:
A specific challenge for informatics will be how to deal 
with ambiguity of data to facilitate data exchange. In 
order to allow assessment of data quality the ‘raw’ data 
needs to be available. In various areas there is a strong 
need for high quality central storage. In some areas dif-
ferent databases will be developed in parallel. In both 
cases efficient search tools, consistent data formats, er-
ror checking and integration between databases is of 
utmost importance. A real challenge for the informatics 
community will be to integrate data from different tech-
nologies gathered at different levels of analysis; this is 
maybe the biggest and most important hurdle to take. 
Finally a serious threat to data gathering and manage-
ment is data loss after funding ceases. Therefore, long-
term funding strategies for integration portals and da-
tabases are essential. 
On anatomical phenotyping of animal models (TBL1)
Approaches to characterize the anatomical phenotype 
of animal models span a wide range of levels and meth-
ods, the choice which depends on the context, model 
and questions to be addressed. Anatomical, or neuro-
pathological, descriptions are typically needed for a) 
validation of reproduction of disease-specific traits, b) 
exploration of pathological processes underlying the 
disease, and c) specification of (in vivo) biomarkers that 
can be used as readout for disease progression or stage. 
Compared to anatomical investigations in ‘normal’ ani-
mal populations, the use of genetically modified mod-
els introduces additional complexity and additional un-
known parameters. This can relate both to variability of 
gene expression, disease phenotype, and comorbidity. 
Further, as traditional journal reports typically describe 
the results of hypothesis driven research in text sup-
plied with selected representative illustrations, only a 
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fraction of the obtained materials are available. As life 
events and normal aging can have profound influence 
on phenotype expression, is it highly important that rel-
evant biographical information are provided and that 
the effect of aging is mapped in some reference popu-
lations. Together, these factors challenge the planning 
and interpretation of experimental research on trans-
genic animal models. Wider access to more complete 
underlying (raw) data, including reference materials 
and negative data, could contribute to reduce these 
problems (see also Boline et al., 2007; Nature Preced-
ings: doi:10.1038/npre.2007.1046.1). 
Recommendations (pertaining to anatomical phenotyp-
ing)
General requirements for all brain-derived data should 
be that: 
•	 Underlying raw data are shared, including ‘negative’ 
or ‘normal’ descriptions, if possible full (whole brain) 
data should be included.
•	 Minimal metadata are provided (should be specified, 
cfr. recommendations in the field; see, e.g. Gibson et 
al., 2008; precedings.nature.com/documents/1720/
version/1).
There is a need for: 
•	 As neurodegenerative diseases occur with increasing 
age, a comprehensive mapping of aging animals (ro-
dent) is needed to describe normal aging processes. 
•	 Recommendations for minimum workflows for vali-
dation / phenotyping of transgenic models.
•	 Consensus in the field about certain models can give 
necessary focus to obtain full descriptions. 
•	 All reported data should be related to a defined 3-D 
framework (standard atlas space, Waxholm space for 
mice).
Because assignment of spatial information is essential, 
it might be possible to delineate some standards or lev-
els of increasing precision: 
1. Text descriptions should employ recognized anatomi-
cal ontology / terminology (see e.g. Bota and Swanson, 
2007; www.incf.org/documents/workshop-reports/
incfworkshop-1st-NeuroanatomicalNomenclature.pdf ).
2. For tomographical / histological data, slice / section 
orientation should be defined relative to atlas space 
(such as flat brain skull position or Waxholm space).
3. Data should be assign standard reference brain 3-D 
coordinates. 
4. If possible, data should be registered / wharped / nor-
malized to a 3-D reference space.
Olaf Riess
We are concentrating on two major issues related to 
animal models of neurodegenerative diseases: (1) what 
are the best models and how to generate these, and (2) 
how do we design and perform preclinical treatment 
studies to achieve most helpful results for subsequent 
human clinical trials.
In several ways, animal models have considerable ad-
vantages over human patients for studies of brain dis-
eases: (i) one can perform numerous treatment studies 
in parallel, even if the drug is not optimized for toxicity, 
(ii) neuropathology can be studied in detail during ini-
tiation and progression of the disease, which is basically 
not possible in humans, (iii) new markers, such as pro-
teins or antibodies, that might be helpful in patients for 
diagnosis can be tested (e.g. see synuclein labeling of 
Lewy bodies in PD), (iv) neurotransmitters can be stud-
ied more easily, and (v) even for imaging, despite the 
small brain and resolution of the images, new tracers 
can be developed. 
For issue (1), model generation, currently BAC overex-
pression is typically used to mimic the expression pat-
tern of the human gene more closely. Also, knockin 
technology is frequently used in several neurodegen-
erative diseases such as AD and PD. Currently there is 
a lack of comparability of existing models. Here, INCF 
could stimulate initiatives to investigate expression 
levels, regions of expression, cellular expression, neu-
ropathology such as degeneration or types of aggre-
gates, stability of phenotype, and progression among 
the different models. Standardization of behavioural or 
neuropathological readouts do not exist, also there is 
no grading system as is usual for human patients. First 
recommendations for phenotyping strategies of mice 
(Crawley 2008) and of a scoring system to phenotype 
transgenic rats (Korenova et al. 2009) have been made 
without general agreement on which terms to use. 
Contribution of the INCF: Stimulating comparative in-
vestigation of disease models, discussing the merits of 
each species, development of standardization, develop-
ment of databases for animal models, and communicat-
ing the importance of standardization and comparabil-
ity to funding agencies.
The second important issue is how to measure efficacy 
of preclinical treatment trials in diseases for which ba-
sically no effective treatment exists and how to adapt 
models and read-outs for future human trials. Imaging 
is widely available for mice, rats, and also for nonhu-
man primates. Tracer concentrations are sometimes 
not measured, and resolution and variance of the mod-
els are still issues (as in humans). Models can be used 
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to test new tracers before use in humans. However, no 
standardization exists and no guideline about whether 
imaging analyses such as MRI, PET or DTI-MRI should be 
included in descriptions of the models. Repetitive stud-
ies are not required (as they are in human trials) even 
though reproducibility is always an issue. For phenotyp-
ing, the question remains how comparable convention-
al phenotyping is compared to automated phenotyp-
ing. What are specific readouts in animals for symptoms 
in human patients (e.g. we lack a choreatic mouse or rat). 
This needs to be defined before initiating comparative 
preclinical trials. However, for some diseases, such as 
ALS, guidelines for preclinical drug interventions have 
been established by a consortium of experts (Ludolph 
et al. 2007). For each model it needs (1) to be discussed, 
which biomarker can be used to monitor treatment suc-
cess, (2) to be defined which specific readouts are want-
ed, which are reproducible, how to reach standardiza-
tion, and what scoring system should be used. 
Contribution of the INCF: Bring groups of experts to-
gether to develop guidelines for preclinical testing of 
models for specific diseases. Develop databases and 
encourage editors of scientific journals to accept “nega-
tive” results. Work towards standards that provide a 
baseline for publishing animal models of neurodegen-
eration.
A third point is which species should be used for neuro-
degenerative disease studies. Each species has advan-
tages and limitations. Each model needs to be evaluat-
ed for use as a mimic of particular aspects of a disease or 
for use as a broadly accepted model. In addition to mice, 
transgenic rat can be used as models of neurodegener-
ation. In the field of neurodegeneration, rats have some 
advantages compared to mice for neurophysiological 
studies, for neurotransplantation, for some behavioural 
tests such as learning, for continuous biomarker sam-
pling such as blood and liquor, for higher resolution in 
in vivo imaging, and for pharmacogenomics because 
rats respond differently than mice.
Contribution of INCF: Bring experts in rat models of 
neurodegeneration together to discuss these issues.
Christian Desaintes 
The European Commission’s contribution towards the 
elucidation of human disease using mouse models
During Framework Programme 6 (FP6), covering the 
period 2002-2006, the European Commission has been 
supporting a wide-ranging and substantial programme 
on mouse functional genomics involving more than a 
dozen large-scale multi-year projects. Some of these 
projects (such as MUGEN, EVI-GENORET, EuroHear, etc.) 
are using the mouse as a model to understand funda-
mental biological processes relevant to human health 
and diseases, while several others (EUCOMM, EUMODIC, 
EURExpress, EMMA, etc.) are generating comprehensive 
resources for the scientific community that should ulti-
mately allow the functional annotation of the mamma-
lian genome. 
Many of these projects are centred on the programme 
of large-scale mutagenesis of coding genes. They en-
compass molecular phenotyping at the tissue level, 
the development and improvement of technologies for 
high-throughput mutagenesis, the production of con-
ditional mutations in ES cells, the derivation of mutant 
mice and their phenotypic determination, and finally 
the archiving and distribution of resources (vectors, mu-
tant ES cells and mice). 
The European mutagenesis programme is coordinated 
with similar efforts in North America grouped under the 
International Knockout Mouse Consortium (IKMC). This 
initiative includes three funding agencies (European 
Commission, Genome Canada, and the United States 
National Institutes of Health) and their funded muta-
genesis programmes (EUCOMM, NorCOMM, KOMP) as 
well as the trap resources that have been generated by 
the Texas Institute of Genomic Medicine. In FP7 (cover-
ing the period 2007-2013), the European Commission 
continues to support several projects where the mouse 
plays a key role in elucidating the complexity of basic 
biological processes at a system level as a way to un-
derstand the molecular basis of human development in 
health and disease (among which several neurological 
disorders). The European Commission also continues to 
support the IKMC with the funding of five projects cur-
rently (I-DCC, CREATE, Infrafrontier, EMMAservice and 
PhenoScale) that promote the best use of the IKMC re-
sources. 
A call for proposals was recently published for possible 
funding of an additional large project that should valo-
rise the IKMC mutant resources and make them avail-
able to the biomedical scientific community as a unique 
and comprehensive tool to address the role of each 
gene in development, health, and disease. Despite this 
considerable effort, further ambitious actions, such as 
the systematic phenotyping of mutants, could be con-
sidered in a worldwide endeavour, to fully capitalise on 
the investments made in the IKMC, thereby providing 
the scientific community with an invaluable resource 
for understanding human health and disease. A con-
ference might also be organised in spring 2010 with 
the aim of demonstrating the complementary nature 
of mouse models and medical research on human dis-
eases (e.g. neurodegeneration, cancer, cardiovascular 
disease, diabetes). A strong focus of this conference 
should be on the identification and discussion of mu-
tual requirements to unravel the molecular basis of the 
disease mechanism. 
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